In addition, the treatment of early stage and advanced prostate cancer cells with the selective SPHK2 inhibitor, ABC294640, induces a reduction in Myc and androgen receptor (AR) expression, and this is associated with significant inhibition of growth, proliferation, and cell cycle progression [90]. This evidence concerns the gene MYC and prostate carcinoma.